| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.13 | 0.03 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.03 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.03 |